Literature DB >> 27429514

Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.

Hara Prasad Pati1, Prashant Sharma2.   

Abstract

Entities:  

Year:  2016        PMID： 27429514      PMCID： PMC4930764          DOI： 10.1007/s12288-016-0700-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  18 in total

1.  Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Authors:  Tiziano Barbui; Alessandra Carobbio; Guido Finazzi; Alessandro M Vannucchi; Giovanni Barosi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Silvia Salmoiraghi; Pio Zilio; Cosimo Ottomano; Roberto Marchioli; Ivan Cuccovillo; Barbara Bottazzi; Alberto Mantovani; Alessandro Rambaldi
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

2.  JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Authors:  Marina Panova-Noeva; Marina Marchetti; Sabrina Buoro; Laura Russo; Annamaria Leuzzi; Guido Finazzi; Alessandro Rambaldi; Cosimo Ottomano; Hugo Ten Cate; Anna Falanga
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

3.  JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.

Authors:  Laura Villani; Gaetano Bergamaschi; Massimo Primignani; Vittorio Rosti; Adriana Carolei; Valentina Poletto; Paolo Catarsi; Ambra Spolverini; Alessandro M Vannucchi; Giovanni Barosi
Journal:  Leuk Res       Date:  2011-09-03       Impact factor: 3.156

Review 4.  Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.

Authors:  M A Elliott; A Tefferi
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

5.  Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

Authors:  N Maugeri; G Giordano; M P Petrilli; V Fraticelli; G de Gaetano; C Cerletti; S Storti; M B Donati
Journal:  J Thromb Haemost       Date:  2006-09-06       Impact factor: 5.824

6.  Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.

Authors:  Silvia Pascale; Giovanna Petrucci; Alfredo Dragani; Aida Habib; Francesco Zaccardi; Francesca Pagliaccia; Davide Pocaterra; Enzo Ragazzoni; Giancarlo Rolandi; Bianca Rocca; Carlo Patrono
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

7.  Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.

Authors:  Sudha Sazawal; Jyoti Bajaj; Sunita Chikkara; Sonal Jain; Rahul Bhargava; Manoranjan Mahapatra; Renu Saxena
Journal:  Indian J Med Res       Date:  2010-10       Impact factor: 2.375

8.  Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.

Authors:  Luciana Teofili; Maurizio Martini; Maria Grazia Iachininoto; Sara Capodimonti; Eugenia Rosa Nuzzolo; Lorenza Torti; Tonia Cenci; Luigi Maria Larocca; Giuseppe Leone
Journal:  Blood       Date:  2011-01-06       Impact factor: 22.113

9.  Thrombotic complications of polycythemia vera.

Authors:  S Varma; Aman Sharma; Pankaj Malhotra; S Kumari; S Jain; N Varma
Journal:  Hematology       Date:  2008-12       Impact factor: 2.269

10.  Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.

Authors:  Marina Marchetti; Elisabetta Castoldi; Henri M H Spronk; René van Oerle; Donatella Balducci; Tiziano Barbui; Jan Rosing; Hugo Ten Cate; Anna Falanga
Journal:  Blood       Date:  2008-09-03       Impact factor: 22.113
View more
  1 in total

1.  Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017.

Authors:  Tathagata Chatterjee; Ankur Ahuja
Journal:  Indian J Hematol Blood Transfus       Date:  2018-02-03       Impact factor: 0.900
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.